Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diet study hopes to tame gut inflammation in polyp patients

NCT ID NCT06603519

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a two-week plant-based Mediterranean diet can change gut bacteria and reduce inflammation in people who have had colon polyps removed. Thirty participants will eat high-fiber meals delivered to their homes, and researchers will track changes in blood and stool samples over eight weeks. The goal is to understand how diet affects the gut microbiome and immune system in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Modified plant-based Mediterranean diet (high-fiber meals)
What this could lead to
If it works, this could point toward a dietary approach to reduce inflammation and improve gut health in people prone to colon polyps.
What could go wrong
This is a very small, early study with only 30 participants and no control group, so results may not apply broadly. Dietary changes can also cause temporary digestive discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Due for 2nd or 3rd colonoscopy with prior diagnosis of tubular, villous, or serrated polyps but no current diagnosis of CRC. Exclusion Criteria: 1. Inability to provide informed consent and engage in informed consent procedures. 2. Participants who suffer from allergic reactions to, or are unwilling to consume, any components of the dietary intervention. 3. Pregnant 4. Serious illness and in hospice or palliative care for terminal disease 5. Swallowing issues, including self-reported difficulty tolerating solids or liquids. 6. Active antibiotics use for an ongoing acute infection. 7. Any disorder, unwillingness, or inability not covered by any other exclusion criteria which, in the investigator's and/or team's opinion jeopardizes the safety of the participant or others or would interfere with adherence to the protocol. 8. Participants who plan to relocate to an area not served by UCSD or travel plans that do not permit completion of the study. 9. Possible ethanol (alcohol) use disorder defined by Alcohol Use Disorders Identification Test (AUDIT) score of \>15 Uncontrolled disease states: 10. Hyper-tension \>160/100mmHg 11. Exacerbation of underlying gastrointestinal disease, including chronic inflammatory bowel disease or other malabsorptive disorders 12. Decompensated cirrhosis 13. Previously diagnosed Diabetes Mellitus with HbA1c \>9% at screening 14. Newly diagnosed diabetes within the past three months, or HbA1c \>6.5% at screening in a person not previously diagnosed with diabetes. 15. Participants with a history of end-stage renal disease (ESRD) on hemodialysis 16. Active infectious diseases (e.g., active tuberculosis \< 3 months from symptom onset or positive test, COVID \< 1 month from symptom onset or positive test) 17. Participants who require dietary restrictions due to a medical condition or are on a prescribed diet for underlying chronic diseases. 18. Participants with Type 1 or Type 2 diabetes on insulin 19. Participants aged 2: 75 years with Type 2 diabetes taking prescribed medications that can cause hypoglycemia (e.g., sulfonylureas, glinides), or on a prescribed diet 20. Hospitalization for a chronic disease (e.g., congestive heart failure, stroke) within the past three months 21. Requiring transfusions/apheresis during study period 22. Participants with a current diagnosis of, or who have received treatment for, bulimia or anorexia nervosa within the past 3 years 23. Participants with major psychiatric disorders, including major depression, schizophrenia, or psychosis, who have been hospitalized in the past six (6) months or are currently enrolled in treatment programs. 24. Hemoglobin \<9.5 g/dL at screening 25. Myocardial infarction, invasive cardiac procedure, participation in a cardiac or acute rehabilitation programs, transient ischemic attacks, or unstable arrhythmias within the past 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Diego Altman Clinical and Translational Research Institute

    San Diego, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.